New combo therapy shows promise for tough colorectal cancer
NCT ID NCT03290937
First seen Nov 03, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-phase trial tested a combination of two antibody drugs (utomilumab and cetuximab) plus chemotherapy (irinotecan) in 34 people with advanced colorectal cancer that had spread. The main goals were to find the safest dose and see if the tumors shrank. The study is complete, and results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV COLORECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.